ABSTRACT This commentary addresses issues raised during the infected blood inquiry (IBI) which ran for 6 years before concluding in 2024. Reference is made to publications in issues of Haemophilia and other journals, addressing the outcomes of the IBI from various perspectives. The author draws on his personal experience, as a patient who also made a career as a plasma fractionation scientist, to critique some of the IBI's salient conclusions. The commentary seeks to let the dust settle around the IBI by including features which have been inadequately addressed, in the author's view as a participant in the events covered by the inquiry.
Albert Farrugia (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: